Neuron23

American clinical stage biotechnology company in South San Francisco, California, founded in 2018, which develops precision medicines for neurological and immunological disease. Combines genetics, machine learning and biomarker development to select patients likely to respond, with its lead programme a brain penetrant LRRK2 kinase inhibitor for genetically defined Parkinson's disease paired with a companion diagnostic, alongside a TYK2 inhibitor programme in immunology.